CRIS Curis Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CRIS

Price (delayed)

$0.4286

Market cap

$50.45M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.5

Enterprise value

$34.01M

Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer. In 2015, Curis entered into a collaboration with Aurigene in the areas of ...

Highlights
CRIS's debt is down by 24% YoY and by 8% from the previous quarter
Curis's EPS has increased by 19% YoY and by 9% QoQ
The equity has plunged by 58% YoY and by 28% from the previous quarter
CRIS's quick ratio is down by 26% since the previous quarter and by 25% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://www.curis.com
Peers: EXEL EBS CLDX PFE

Key stats

What are the main financial stats of CRIS
Market
Shares outstanding
117.7M
Market cap
$50.45M
Enterprise value
$34.01M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.58
Price to sales (P/S)
4.06
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.33
Earnings
Revenue
$10.21M
EBIT
-$48.14M
EBITDA
-$46.57M
Free cash flow
-$45.51M
Per share
EPS
-$0.5
Free cash flow per share
-$0.47
Book value per share
$0.27
Revenue per share
$0.11
TBVPS
$0.78
Balance sheet
Total assets
$84.31M
Total liabilities
$58.08M
Debt
$3.38M
Equity
$26.22M
Working capital
$58.17M
Liquidity
Debt to equity
0.13
Current ratio
7.01
Quick ratio
6.8
Net debt/EBITDA
0.35
Margins
EBITDA margin
-456.3%
Gross margin
97.7%
Net margin
-471.7%
Operating margin
-456.5%
Efficiency
Return on assets
-46.9%
Return on equity
-116.6%
Return on invested capital
-77.9%
Return on capital employed
-64.5%
Return on sales
-471.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CRIS stock price

How has the Curis stock price performed over time
Intraday
-4.86%
1 week
-8.65%
1 month
-27.36%
1 year
-41.78%
YTD
-22.07%
QTD
-48.36%

Financial performance

How have Curis's revenue and profit performed over time
Revenue
$10.21M
Gross profit
$9.98M
Operating income
-$46.59M
Net income
-$48.14M
Gross margin
97.7%
Net margin
-471.7%
The net income is up by 15% year-on-year and by 8% since the previous quarter
CRIS's net margin is up by 12% YoY and by 6% from the previous quarter
Curis's operating income has increased by 12% YoY and by 6% QoQ
CRIS's operating margin is up by 8% year-on-year and by 4.1% since the previous quarter

Growth

What is Curis's growth rate over time

Valuation

What is Curis stock price valuation
P/E
N/A
P/B
1.58
P/S
4.06
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.33
Curis's EPS has increased by 19% YoY and by 9% QoQ
The equity has plunged by 58% YoY and by 28% from the previous quarter
The price to book (P/B) is 7% lower than the last 4 quarters average of 1.7
CRIS's price to sales (P/S) is 81% lower than its 5-year quarterly average of 20.9 and 35% lower than its last 4 quarters average of 6.2
The revenue has declined by 3.9% year-on-year

Efficiency

How efficient is Curis business performance
CRIS's return on equity has dropped by 70% year-on-year and by 12% since the previous quarter
The ROIC has decreased by 36% YoY and by 3.2% from the previous quarter
The company's return on assets fell by 25% YoY and by 2.4% QoQ
Curis's return on sales has increased by 12% YoY and by 6% QoQ

Dividends

What is CRIS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CRIS.

Financial health

How did Curis financials performed over time
The company's total assets is 45% higher than its total liabilities
The company's total assets fell by 35% YoY and by 11% QoQ
The current ratio has declined by 28% since the previous quarter and by 25% year-on-year
CRIS's debt is 87% less than its equity
The debt to equity has soared by 86% YoY and by 30% QoQ
The equity has plunged by 58% YoY and by 28% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.